India Pharma Outlook Team | Tuesday, 10 May 2022
The United States Food and Drug Administration (U.S. FDA) has granted Glenmark Pharmaceuticals Inc., USA tentative approval for Calcipotriene and Betamethasone
Dipropionate Foam, 0.005 per cent and 0.064 per cent, the generic version of Enstilar®1 Foam, 0.005 per cent and 0.064 per cent, by Leo Pharma AS. According to IQVIATM sales data for the 12-month period ending March 2022, the Enstilar® Foam market achieved annual sales of approximately $115.2 million. Glenmark’s current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDAs pending approval with the U.S. FDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
, CDSCO.jpg)
.jpg)